Alcobra Ltd. to Present at Upcoming Investment Conferences

TEL AVIV, Israel, Jan. 28, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced upcoming corporate presentations at the BIO CEO and Investor Conference and the 1st Annual Neuroscience BioPartnering & Investment Forum.

BIO CEO & Investor Conference
Date:Monday, February 8
Time:8:30am ET
Location: Waldorf Astoria, New York, NY

1st Annual Neuroscience BioPartnering & Investment Forum
Date: Tuesday, February 23
Time: 4:10pm ET
Location: The New York Academy of Sciences, New York, NY

About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website,, the content of which is not incorporated herein by reference.

U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661

Source:Alcobra Ltd.